La fourniture de sang et de produits sanguins sûrs et efficaces pour la transfusion ou la fabrication d’autres produits sanguins fait intervenir un certain nombre de processus, allant de la sélection des donneurs de sang et de la collecte, au traitement et au dépistage des dons de sang ainsi qu...’à l’analyse des échantillons des malades, à la délivrance de sang compatible et à son administration au patient. Il existe un risque d’erreur à chaque étape de la « chaîne de transfusion », et une défaillance à une quelconque de ces étapes peut avoir des conséquences graves pour les receveurs du sang ou des produits sanguins. Si la transfusion sanguine peut sauver des vies, elle comporte aussi des risques, en particulier la transmission des infections par le sang.
Le dépistage des infections transmissibles par transfusion (ITT) en vue d’exclure les dons de sang présentant un risque de transmettre une infection du donneur aux receveurs est une étape critique du processus visant à garantir au mieux la sécurité des transfusions. Un dépistage efficace des agents transmissibles par le sang les plus courants et les plus dangereux peut réduire le risque de transmission à des niveaux très faibles.
more
Временные рекомендации
20 марта 2020 г.
В этом документе представлены временные рекомендации, касающиеся управления поставками донорской крови в рамках ответных ...ер на пандемическую вспышку коронавирусной инфекции (COVID-19). Он предназначен для служб крови, национальных органов общественного здравоохранения и других органов, ведающих поставками донорской крови и ее компонентов, а также интеграцией системы обеспечения крови в систему общественного здравоохранения. ВОЗ будет обновлять эти рекомендации по мере поступления новой информации.
more
The paper provides the rationale for these recommendations, which are based on analyses of data from the TRACT trial.
El “Manual de Procedimientos Operativos de Técnicas Inmunohematológicas efectuadas en Servicios de Sangre”, otorga los lineamientos generales para que los Servicios de Sangre (Bancos de Sangre y Servicios de Transfusión) trabajen de manera uniforme, ordenada y correcta, permitiendo mejorar la... calidad de las Técnicas Inmunohematológicas que se realizan de manera rutinaria, aportando información científica actualizada con técnicas estandarizadas, cuya aplicación es a Nivel Nacional.
more
Mais pessoas morrem a cada ano de doenças cardiovasculares do que de qualquer outra causa. Mais de três quartos das mortes por doenças cardíacas e acidentes vasculares cerebrais ocorrem em países de baixa e média renda. A hipertensão - ou pressão alta - é uma condição médica grave que au...menta significativamente o risco de doenças cardíacas, cerebrais, renais e outras doenças. A hipertensão pode ser definida usando níveis específicos de pressão sistólica e diastólica ou o uso reportado de medicamentos anti-hipertensivos.
more
La schistosomiase est une parasitose aiguë et chronique provoquée par des vers (trématodes) du genre Schistosoma. Selon les estimations, au moins 251,4 millions de personnes avaient besoin d’un traitement préventif en 2021. Le traitement préventif, qui devrait être renouvelé pendant un cert...ain nombre d’années, permettra de réduire et de prévenir la morbidité. La transmission de la schistosomiase est avérée dans 78 pays. Cependant, la chimioprophylaxie de la maladie, dont le but est de traiter à grande échelle les populations et les communautés, n’est nécessaire que dans 51 pays d’endémie où la transmission est de modérée à forte.
more
La esquistosomiasis es una enfermedad parasitaria aguda y crónica causada por duelas sanguíneas (trematodos) del género Schistosoma. Se calcula que al menos 251,4 millones de personas necesitaron tratamiento profiláctico en 2021. El tratamiento profiláctico, que se debería repetir durante algu...nos años, permite reducir y prevenir la morbilidad. Hay constancia de la transmisión de la enfermedad en 78 países. Sin embargo, la quimioprofilaxis para la esquistosomiasis, en la que se aplica un tratamiento a gran escala a personas y comunidades, solamente se requiere en 51 países en los que la enfermedad es endémica y tienen una transmisión de moderada a alta.
more
داء البلهارسيات هو مرض طفيلي حاد ومزمن تسبّبه الديدان المثقوبة الدموية (المثقوبات) من جنس البلهارسية. وتشير التقديرات إلى أن 251.4 مليون شخص على الأقل كانوا بحاجة إلى ...لعلاج الوقائي من داء البلهارسيات في عام 2021. ومن شأن العلاج الوقائي، الذي ينبغي تكراره على مدى عدة سنوات، أن يحد من المراضة ويمنعها. وقد أُبلغ عن سريان المرض في 78 بلداً. ومع ذلك، فإن العلاج الكيميائي الوقائي لداء البلهارسيات الذي يُستهدف فيه الأشخاص والمجتمعات المحلية بالعلاج على نطاق واسع، لا يلزم إلا في 51 بلداً موطوناً يشهد مستويات سريان المرض المتوسطة أو العالية.
more
Шистосомоз является острой и хронической паразитарной болезнью, вызываемой кровяными сосальщиками (трематодными червями) из рода Schistosoma. В 2021 г. количество нуждаю...ихся в профилактическом лечении шистосомоза оценивалось на уровне не менее 251,4 млн человек. Профилактическое лечение, которое необходимо повторять через несколько лет, снижает и предотвращает заболеваемость шистосомозом. Передача шистосомоза регистрируется в 78 странах. Однако профилактическая химиотерапия в рамках широкомасштабного лечения шистосомоза среди людей и общин требуется только в 51 эндемичной стране с умеренными и высокими показателями передачи инвазии.
more
WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths.
Despite being preventable and treatable, PPH results in around 70 000 de...aths every year. For those who survive, it can cause disabilities and psychological trauma that last for years.
“Severe bleeding in childbirth is one of the most common causes of maternal mortality, yet it is highly preventable and treatable,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This new roadmap charts a path forward to a world in which more women have a safe birth and a healthy future with their families.”
The Roadmap aims to help countries address stark differences in survival outcomes from PPH, which reflect major inequities in access to essential health services. Over 85% of deaths from PPH happen in sub-Saharan Africa and South Asia. Risk factors include anaemia, placental abnormalities, and other complications in pregnancy such as infections and pre-eclampsia.
Many risk factors can be managed if there is quality antenatal care, including access to ultrasound, alongside effective monitoring in the hours after birth. If bleeding starts, it also needs to be detected and treated extremely quickly. Too often, however, health facilities lack necessary healthcare workers or resources, including lifesaving commodities such as oxytocin, tranexamic acid or blood for transfusions.
“Addressing postpartum haemorrhage needs a multipronged approach focusing on both prevention and response - preventing risk factors and providing immediate access to treatments when needed - alongside broader efforts to strengthen women’s rights,” said Dr Pascale Allotey, WHO Director for Sexual and Reproductive Health and HRP, the UN’s special programme on research development and training in human reproduction. “Every woman, no matter where she lives, should have access to timely, high quality maternity care, with trained health workers, essential equipment and shelves stocked with appropriate and effective commodities – this is crucial for treating postpartum bleeding and reducing maternal deaths.”
more
Cardiovascular diseases (CVDs) have collectively remained the leading causes of death worldwide and substantially contribute to loss of health and excess health system costs. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study has tracked trends in death and disability since 1990 a...nd has provided an updated perspective on the status of cardiovascular health globally, regionally, and nationally.
more
Severe and difficult asthma in a low- and middle-income country (LMIC) can relate to lack of availability of basic medications; potentially reversible factors such as poor adherence or comorbidities such as obesity inhibiting a good response to treatment; and (rarely) true severe, therapy-resistant ...asthma. However, definitions of severity should encompass not merely doses of prescribed medication, but also underlying risk. The nature of asthmatic airway disease shows geographical variation, and LMIC asthma should not be assumed to be phenotypically the same as that in high-income countries (HICs). The first assessment step is to ensure another diagnosis is not being missed. Largely, political action is needed if children with asthma are to get access to basic medications. If a child is apparently not responding to low dose, simple medications, the next step is not to increase the dose but perform a detailed assessment of what factors (for example co-morbidities such as obesity, or social factors like poor adherence) are inhibiting a treatment response; in most cases, an underlying reason can be found. An assessment of risk of future severe asthma attacks, side-effects of medication and impaired lung development is also important. True severe, therapy-resistant asthma is rare and there are multiple underlying molecular pathologies. In HICs, steroid-resistant eosinophilia would be treated with omalizumab or mepolizumab, but the cost of these is prohibitive in LMICs, the biomarkers of successful therapy are likely only relevant to HICs. In LMICs, a raised blood eosinophil count may be due to parasites, so treating asthma based on the blood eosinophil count may not be appropriate in these settings.
more